SYM FINANCIAL Corp Buys 14,531 Shares of Pfizer Inc. (NYSE:PFE)

SYM FINANCIAL Corp boosted its position in Pfizer Inc. (NYSE:PFE) by 209.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,483 shares of the biopharmaceutical company’s stock after purchasing an additional 14,531 shares during the quarter. SYM FINANCIAL Corp’s holdings in Pfizer were worth $570,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently added to or reduced their stakes in the business. Retirement Wealth Solutions LLC bought a new position in shares of Pfizer in the 4th quarter worth $26,000. Gladius Capital Management LP raised its position in Pfizer by 102.8% during the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 38,015 shares in the last quarter. Quarry LP bought a new stake in Pfizer during the second quarter worth about $31,000. Teachers Insurance & Annuity Association of America purchased a new position in shares of Pfizer in the 3rd quarter worth about $35,000. Finally, Joseph Group Capital Management increased its position in shares of Pfizer by 168.3% during the 3rd quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 771 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

PFE has been the subject of several research reports. Bank of America reaffirmed a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. Truist Financial cut their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. Sanford C. Bernstein started coverage on Pfizer in a research report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price objective for the company. StockNews.com lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Finally, Wolfe Research initiated coverage on shares of Pfizer in a research report on Friday, November 15th. They set an “underperform” rating and a $25.00 price target on the stock. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Trading Down 1.5 %

NYSE PFE opened at $26.51 on Friday. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The stock’s fifty day moving average price is $26.27 and its 200-day moving average price is $27.87. The stock has a market cap of $150.20 billion, a P/E ratio of 35.82, a P/E/G ratio of 0.64 and a beta of 0.64.

Pfizer Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a dividend of $0.43 per share. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a yield of 6.49%. The ex-dividend date is Friday, January 24th. Pfizer’s dividend payout ratio (DPR) is currently 232.44%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.